Premium
Outcome of surgical treatment for recurrent thymic epithelial tumors with reference to world health organization histologic classification system
Author(s) -
Okumura Meinoshin,
Shiono Hiroyuki,
Inoue Masayoshi,
Tanaka Hisaichi,
Yoon HyunEng,
Nakagawa Katsuhiro,
Matsumura Akihide,
Ohta Mitsunori,
Iuchi Keiji,
Matsuda Hikaru
Publication year - 2006
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.20671
Subject(s) - medicine , resection , surgical resection , thymic carcinoma , carcinoma , surgery , chemotherapy
Background and Objectives The aim of this study was to clarify the significance of surgical treatment for recurrent thymic epithelial tumors with reference to the World Health Organization (WHO) histological classification system. Patients Among 67 patients with tumor recurrence, 22 underwent a re‐resection. There were 1 patient with a type AB tumor, 5 with type B1 tumors, 10 with type B2 tumors, 5 with type B3 tumors, and 1 with a carcinoma. Results The 10‐year survival rate following the initial resection was 70% in patients who underwent a re‐resection and 35% in those who did not. The average intervals from the initial resection to re‐resection were 10.3, 7.8, 6.0, 2.4, and 2.6 years for patients with type AB, B1, B2, B3 tumors, and carcinoma, respectively. The patient with a type AB tumor was alive at 2.4 years after re‐resection, 12.7 years after the initial resection. The 5‐year survival rates following re‐resection in the patients with type B1, B2, and B3 tumors were 100, 56, and 60, respectively. The patient with a carcinoma died as a result of the tumor 2 years after re‐resection. Conclusion WHO histological classification indicates the outcome of surgical treatment for recurrent thymic epithelial tumors. J. Surg. Oncol. 2007;95:40–44. © 2006 Wiley‐Liss, Inc.